CLINICAL RESEARCH: CLINICAL TRIAL
Lack of Evidence of a Clopidogrel–Statin Interaction in the CHARISMA Trial
Jacqueline Saw, MD*,
Danielle M. Brennan, MS ,
Steven R. Steinhubl, MD ,
Deepak L. Bhatt, MD,
Koon-Hou Mak, MD ,
Keith Fox, MB, ChB||,
Eric J. Topol, MD#,* on behalf of the CHARISMA Investigators
* Division of Cardiology, Vancouver General Hospital, University of British Columbia, Vancouver, British Columbia, Canada
Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio
Department of Cardiovascular Medicine, University of Kentucky, Lexington, Kentucky
Gleneagles Medical Center, Singapore
|| University and Royal Infirmary of Edinburgh, Edinburgh, Scotland, United Kingdom
# Department of Cardiovascular Diseases, Scripps Clinic, La Jolla, California.
Manuscript received November 7, 2006;
revised manuscript received January 19, 2007,
accepted January 22, 2007.
* Reprint requests and correspondence: Dr. Eric J. Topol, Director, Scripps Translational Science Institute, Chief Academic Officer, Scripps Health, Professor of Translational Genomics, The Scripps Research Institute, Scripps Clinic, Division of Cardiovascular Diseases, 10666 North Torey Pines Road, Mail Drop SW206, La Jolla, California 92037. (Email: etopol{at}scripps.edu).
Objectives: The purpose of this study was to evaluate the potential impact of clopidogrel and statin interaction in a randomized, placebo-controlled trial with long-term follow-up.
Background: There are conflicting data regarding whether statins predominantly metabolized by CYP3A4 reduce the metabolism of clopidogrel to its active metabolite and diminish its clinical efficacy.
Methods: The CHARISMA trial was a randomized trial comparing long-term 75 mg/day clopidogrel versus placebo in patients with cardiovascular disease or multiple risk factors on aspirin. The primary end point was a composite of myocardial infarction, stroke, or cardiovascular death at median follow-up of 28 months. We performed a secondary analysis evaluating the interaction of clopidogrel versus placebo with statin administration, categorizing baseline statin use to those predominantly CYP3A4 metabolized (atorvastatin, lovastatin, simvastatin; CYP3A4-MET) or others (pravastatin, fluvastatin; non–CYP3A4-MET).
Results: Of 15,603 patients enrolled, 10,078 received a statin at baseline (8,245 CYP3A4-MET, 1,748 non–CYP3A4-MET) and 5,496 did not. For the overall population, the primary end point was 6.8% with clopidogrel and 7.3% with placebo (hazard ratio [HR] 0.93; p = 0.22). This was similar among patients on CYP3A4-MET (5.9% clopidogrel, 6.6% placebo, HR 0.89; p = 0.18) or non–CYP3A4-MET statin (5.7% clopidogrel, 7.2% placebo, HR 0.78; p = 0.19). There was no interaction between statin types and randomized treatment (p = 0.69). Patients on atorvastatin (n = 4,127) (5.7% clopidogrel, 7.1% placebo, HR 0.80; p = 0.06) or pravastatin (n = 1,440) (5.1% clopidogrel, 7.0% placebo, HR 0.72; p = 0.13) had similar event rates.
Conclusions: Despite theoretic concerns and ex vivo testing suggesting a potential negative interaction with concomitant clopidogrel and CYP3A4-MET statin administration, there was no evidence of an interaction clinically in a large placebo-controlled trial with long-term follow-up.
|
Abbreviations and Acronyms
| | CI = confidence interval | | CYP3A4-MET = cytochrome P450 3A4-metabolized statin | | HR = hazard ratio | | MI = myocardial infarction | | OR = odds ratio |
|
Related Article
-
Clopidogrel–Statin Interaction: Myth or Reality?
- Dominick J. Angiolillo and Fernando Alfonso
J. Am. Coll. Cardiol. 2007 50: 296-298.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
T. Cuisset, C. Frere, J. Quilici, R. Poyet, B. Gaborit, L. Bali, O. Brissy, P.-E. Morange, M.-C. Alessi, and J.-L. Bonnet
Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study.
J. Am. Coll. Cardiol.,
September 22, 2009;
54(13):
1149 - 1153.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Verstuyft, T. Simon, and R. B. Kim
Personalized medicine and antiplatelet therapy: ready for prime time?
Eur. Heart J.,
August 2, 2009;
30(16):
1943 - 1963.
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. R. Desai, J. L. Mega, S. Jiang, C. P. Cannon, and M. S. Sabatine
Interaction between cigarette smoking and clinical benefit of clopidogrel.
J. Am. Coll. Cardiol.,
April 14, 2009;
53(15):
1273 - 1278.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. M. Ho, T. M. Maddox, L. Wang, S. D. Fihn, R. L. Jesse, E. D. Peterson, and J. S. Rumsfeld
Risk of Adverse Outcomes Associated With Concomitant Use of Clopidogrel and Proton Pump Inhibitors Following Acute Coronary Syndrome
JAMA,
March 4, 2009;
301(9):
937 - 944.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Crea, P. G. Camici, R. De Caterina, and G. A. Lanza
CHAPTER 17 Chronic Ischaemic Heart Disease
ESC Textbook of Cardiovascular Medicine,
January 1, 2009;
2(1):
med-9780199566990-chapter - med-9780199566990-chapter.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Erlinge, C. Varenhorst, O. O. Braun, S. James, K. J. Winters, J. A. Jakubowski, J. T. Brandt, A. Sugidachi, A. Siegbahn, and L. Wallentin
Patients With Poor Responsiveness to Thienopyridine Treatment or With Diabetes Have Lower Levels of Circulating Active Metabolite, but Their Platelets Respond Normally to Active Metabolite Added Ex Vivo
J. Am. Coll. Cardiol.,
December 9, 2008;
52(24):
1968 - 1977.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. S. Kleiman
Searching for the Ceiling: New Reflections on the Disposition and Metabolism of Clopidogrel
J. Am. Coll. Cardiol. Intv.,
December 1, 2008;
1(6):
628 - 630.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Bhindi, O. Ormerod, J. Newton, A.P. Banning, and L. Testa
Interaction between statins and clopidogrel: is there anything clinically relevant?
QJM,
December 1, 2008;
101(12):
915 - 925.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R. Carver, S. J. Schuster, and J. H. Glick
In Reply
J. Clin. Oncol.,
November 20, 2008;
26(33):
5486 - 5486.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Siller-Matula, I. Lang, G. Christ, and B. Jilma
Calcium-Channel Blockers Reduce the Antiplatelet Effect of Clopidogrel
J. Am. Coll. Cardiol.,
November 4, 2008;
52(19):
1557 - 1563.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. S. Kleiman
Clopidogrel and Calcium-Channel Antagonists: Another Drug-Drug Interaction for the Ever-Wary Clinician?
J. Am. Coll. Cardiol.,
November 4, 2008;
52(19):
1564 - 1566.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Ang, V. Palakodeti, A. Khalid, S. Tsimikas, Z. Idrees, P. Tran, P. Clopton, N. Zafar, G. Bromberg-Marin, S. Keramati, et al.
Elevated Plasma Fibrinogen and Diabetes Mellitus Are Associated With Lower Inhibition of Platelet Reactivity With Clopidogrel
J. Am. Coll. Cardiol.,
September 23, 2008;
52(13):
1052 - 1059.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Geisler, C. Zurn, M. Paterok, K. Gohring-Frischholz, B. Bigalke, K. Stellos, P. Seizer, B. F. Kraemer, J. Dippon, A. E. May, et al.
Statins do not adversely affect post-interventional residual platelet aggregation and outcomes in patients undergoing coronary stenting treated by dual antiplatelet therapy
Eur. Heart J.,
July 1, 2008;
29(13):
1635 - 1643.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. D. Michelson
P2Y12 Antagonism: Promises and Challenges
Arterioscler Thromb Vasc Biol,
March 1, 2008;
28(3):
s33 - s38.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. N. DeMaria, J. J. Bax, O. Ben-Yehuda, P. Clopton, G. K. Feld, G. S. Ginsburg, B. H. Greenberg, J. D. Knoke, W. Y.W. Lew, J. A.C. Lima, et al.
Highlights of the year in JACC 2007.
J. Am. Coll. Cardiol.,
January 29, 2008;
51(4):
490 - 512.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Statin Clopidogrel Interactions: Are They Clinically Important?
Journal Watch (General),
September 6, 2007;
2007(906):
2 - 2.
[Full Text]
|
|
|
|
|
|
|
D. J. Angiolillo and F. Alfonso
Clopidogrel Statin Interaction: Myth or Reality?
J. Am. Coll. Cardiol.,
July 24, 2007;
50(4):
296 - 298.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Fitzgerald and A. Maree
Aspirin and Clopidogrel Resistance
Hematology,
January 1, 2007;
2007(1):
114 - 120.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
